TY - JOUR
T1 - The burden and costs of sepsis and reimbursement of its treatment in a developing country
T2 - An observational study on focal infections in Indonesia
AU - Purba, Abdul Khairul Rizki
AU - Mariana, Nina
AU - Aliska, Gestina
AU - Wijaya, Sonny Hadi
AU - Wulandari, Riyanti Retno
AU - Hadi, Usman
AU - Hamzah,
AU - Nugroho, Cahyo Wibisono
AU - van der Schans, Jurjen
AU - Postma, Maarten J.
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2020/7
Y1 - 2020/7
N2 - Objectives: This study aimed to determine the burden of sepsis with focal infections in the resource-limited context of Indonesia and to propose national prices for sepsis reimbursement. Methods: A retrospective observational study was conducted from 2013–2016 on cost of surviving and non-surviving sepsis patients from a payer perspective using inpatient billing records in four hospitals. The national burden of sepsis was calculated and proposed national prices for reimbursement were developed. Results: Of the 14,076 sepsis patients, 5,876 (41.7%) survived and 8,200 (58.3%) died. The mean hospital costs incurred per surviving and deceased sepsis patient were US$1,011 (SE ± 23.4) and US$1,406 (SE ± 27.8), respectively. The national burden of sepsis in 100,000 patients was estimated to be US$130 million. Sepsis patients with multifocal infections and a single focal lower-respiratory tract infection (LRTI) were estimated as being the two with the highest economic burden (US$48 million and US$33 million, respectively, within 100,000 sepsis patients). Sepsis with cardiovascular infection was estimated to warrant the highest proposed national price for reimbursement (US$4,256). Conclusions: Multifocal infections and LRTIs are the major focal infections with the highest burden of sepsis. This study showed varying cost estimates for sepsis, necessitating a new reimbursement system with adjustment of the national prices taking the particular foci into account.
AB - Objectives: This study aimed to determine the burden of sepsis with focal infections in the resource-limited context of Indonesia and to propose national prices for sepsis reimbursement. Methods: A retrospective observational study was conducted from 2013–2016 on cost of surviving and non-surviving sepsis patients from a payer perspective using inpatient billing records in four hospitals. The national burden of sepsis was calculated and proposed national prices for reimbursement were developed. Results: Of the 14,076 sepsis patients, 5,876 (41.7%) survived and 8,200 (58.3%) died. The mean hospital costs incurred per surviving and deceased sepsis patient were US$1,011 (SE ± 23.4) and US$1,406 (SE ± 27.8), respectively. The national burden of sepsis in 100,000 patients was estimated to be US$130 million. Sepsis patients with multifocal infections and a single focal lower-respiratory tract infection (LRTI) were estimated as being the two with the highest economic burden (US$48 million and US$33 million, respectively, within 100,000 sepsis patients). Sepsis with cardiovascular infection was estimated to warrant the highest proposed national price for reimbursement (US$4,256). Conclusions: Multifocal infections and LRTIs are the major focal infections with the highest burden of sepsis. This study showed varying cost estimates for sepsis, necessitating a new reimbursement system with adjustment of the national prices taking the particular foci into account.
KW - Developing countries
KW - Focal infection
KW - Hospital costs
KW - Sepsis
KW - Survivors
KW - Universal health insurance
UR - http://www.scopus.com/inward/record.url?scp=85084557653&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2020.04.075
DO - 10.1016/j.ijid.2020.04.075
M3 - Article
C2 - 32387377
AN - SCOPUS:85084557653
SN - 1201-9712
VL - 96
SP - 211
EP - 218
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -